Reply to the commentary on "Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis"

PSY-PGx Consortium

doi:10.1016/j.euroneuro.2025.11.003

Reply to the commentary on "Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis"

PSY-PGx Consortium

Research output: Contribution to Journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	14-16
Number of pages	3
Journal	European Neuropsychopharmacology
Volume	102
Early online date	22 Nov 2025
DOIs	https://doi.org/10.1016/j.euroneuro.2025.11.003
Publication status	Published - Jan 2026

Funding

The PSY-PGx study was supported by the European Union´s Horizon 2020 Research and Innovation Program (EU.3.1.3. Treating and managing disease, Grant agreement no 945151 ). The funder had no role in the writing of this letter.

Funders	Funder number
Horizon 2020 Framework Programme	945151

Access to Document

10.1016/j.euroneuro.2025.11.003Licence: CC BY

Persistent URL (handle)

Persistent link

Cite this

@article{12752b7ebe9a47379af656d74dfa4999,

title = "Reply to the commentary on {"}Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis{"}",

author = "Fares-Otero, \{Natalia E\} and Monika Budde and Jonathan Laatsch and Mathias Harrer and Teuntje Pelgrim and Alexandra Philipsen and Urs Heilbronner and Eduard Vieta and Westrhenen, \{Roos van\} and \{PSY-PGx Consortium\}",

year = "2026",

month = jan,

doi = "10.1016/j.euroneuro.2025.11.003",

language = "English",

volume = "102",

pages = "14--16",

journal = "European Neuropsychopharmacology",

issn = "0924-977X",

publisher = "Elsevier B.V.",

}

Reply to the commentary on "Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders: A systematic review and meta-analysis". / PSY-PGx Consortium.
In: European Neuropsychopharmacology, Vol. 102, 01.2026, p. 14-16.

Research output: Contribution to Journal › Article › Academic › peer-review

TY - JOUR

T1 - Reply to the commentary on "Efficacy of pharmacogenetic (PGx)-guided antidepressant treatment on functional outcomes and quality of life in adults with anxiety and affective disorders

T2 - A systematic review and meta-analysis"

AU - Fares-Otero, Natalia E

AU - Budde, Monika

AU - Laatsch, Jonathan

AU - Harrer, Mathias

AU - Pelgrim, Teuntje

AU - Philipsen, Alexandra

AU - Heilbronner, Urs

AU - Vieta, Eduard

AU - Westrhenen, Roos van

AU - PSY-PGx Consortium

PY - 2026/1

Y1 - 2026/1

U2 - 10.1016/j.euroneuro.2025.11.003

DO - 10.1016/j.euroneuro.2025.11.003

M3 - Article

C2 - 41275773

SN - 0924-977X

VL - 102

SP - 14

EP - 16

JO - European Neuropsychopharmacology

JF - European Neuropsychopharmacology

ER -